drugset / Trial / NCT00187005

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00187005

Phase 3 Terminated 53 enrolled St. Jude Children's Research Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.

Timeline

Start
1998-07
Primary completion
2002-07
Completion
2002-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 2000 mg/m2 Intravenous
Subject Daunorubicin Small molecule 25 mg/m2 Intravenous
Subject Dexamethasone Small molecule 8 mg/m2 Oral
Subject Etoposide Small molecule 300 mg/m2 Intravenous
Subject Idarubicin Small molecule 5 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 25 mg/m2 Oral
Subject MERCAPTOPURINE ANHYDROUS Small molecule 75 mg/m2 Oral
Subject Methotrexate Small molecule 40 mg/m2 Intravenous
Subject Methotrexate Small molecule 2250 mg/m2 Intravenous
Subject Methotrexate Small molecule 2500 mg/m2 Intravenous
Subject Methotrexate Small molecule 4500 mg/m2 Intravenous
Subject Methotrexate Small molecule 5000 mg/m2 Intravenous
Subject Pegaspargase Protein / enzyme biologic 2500 unknown Intramuscular
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 unknown Intramuscular